Good Manufacturing Practice certification reinforces high company standards for product safety, consistency and quality
TORONTO, June 25, 2018 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) ("Liberty" or the "Company") today announced it has received Good Manufacturing Practice ("GMP") approval from SAI Global for the Company's greenhouse and production facilities in Alachua County, Florida. The GMP certificate was earned in advance of Liberty's July 5th deadline for its processing facilities, confirming the site's compliance with FDA's food safety and packaging GMPs.
"The Good Manufacturing Practice certification is another testament to our commitment to excellence and precision dosing of cannabis products," said CEO George Scorsis. "We strive to set the bar for safety, quality and consistency as we expand in response to the rapidly growing need in the emerging cannabis industry. It is a great honor and a privilege to receive a GMP certification compliant to the FDA standard that validates all the exhaustive work our team has done to ensure Liberty products are the very best."
"In anticipation of expected state approval of edibles, we have built an all-encompassing food safety plan which goes above and beyond regulatory requirements," said Director of Compliance and Regulatory, Jessica Engle. "We want to give our consumers 100% confidence that the products they purchase are guaranteed safe and this certification reinforces that promise."
About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. is an investor and operator in the cannabis market, capitalizing on new and existing opportunities in U.S. states where cannabis is legal. Liberty's stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities while keeping consumers well-being at the forefront of what we do. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to consumers.
For more information, please visit libertyhealthsciences.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the production and sale of edible products in Florida, expected state approval of edibles, and the Company's future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
SOURCE Liberty Health Sciences Inc.
For further information: For Canadian media inquiries, please contact: Hilary Sloan, Edelman, (416) 908-2134, email@example.com; For U.S. media inquiries, please contact: David Schull or Nic Johnson, Russo Partners, (858) 717-2310, firstname.lastname@example.org, email@example.com